查找临床试验

已按「间皮瘤」检索,对应国际通用词 mesothelioma

试验不在中国怎么办?

共找到 11 项正在招募的试验(在中国/港澳台设有中心)

数据更新于 11:24,每 5 分钟自动同步
正在招募I 期中国有中心NCT06196294

GPC3/Mesothelin-CAR-γδT Cells Against Cancers

China

年龄 18 Years75 Years

Second Affiliated Hospital of Guangzhou Medical University

正在招募I 期中国有中心NCT06566079

Study of ISM6331 in Participants With Advanced/Metastatic Malignant Mesothelioma or Other Solid Tumors

United States、China

年龄 18 Years不限

InSilico Medicine Hong Kong Limited

正在招募II 期中国有中心NCT05188859

First Line Sintilimab Combined With Anlotinib and Platinum Doublet Chemotherapy in Malignant Pleural Mesothelioma

China

年龄 18 Years不限

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

正在招募II 期中国有中心NCT06875076

Multicenter Single-Arm Study of Ivonescimab (AK112) Combined with Chemotherapy in Pretreated Pleural Mesothelioma

China

年龄 18 Months75 Months

The First Hospital of Jilin University

正在招募I 期 / II 期中国有中心NCT07510815

Dual-Target MSLN/FAP CAR-NK Cells for Pleural and Peritoneal Mesothelioma

China

年龄 18 Years75 Years

Beijing Biotech

正在招募II 期中国有中心NCT06535607

Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors

United States、Australia、Brazil、Canada、China 等 12 国

年龄 18 Years不限

AstraZeneca

正在招募I 期中国有中心NCT06726564

A Study of MT027 in Patients with Pleural Malignant Tumors

China

年龄 18 Years不限

Suzhou Maximum Bio-tech Co., Ltd.

正在招募I 期 / II 期中国有中心NCT05579366

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

United States、China、Japan

年龄 18 Years不限

Genmab

正在招募II 期中国有中心NCT06543069

Sintilimab, Bevacizumab, Pemetrexed, and Cisplatin for Unresectable MPeM

China

年龄 18 Years不限

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

正在招募不适用中国有中心NCT07330271

PTC-Guided Therapy for Peritoneal Mesothelioma

China

年龄 18 Years85 Years

Beijing Tsinghua Chang Gung Hospital

正在招募I 期中国有中心NCT03917043

APG-2449 in Patients With Advanced Solid Tumors

China

年龄 18 Years不限

Ascentage Pharma Group Inc.